US2956062A - Esters of amino alcohols - Google Patents

Esters of amino alcohols Download PDF

Info

Publication number
US2956062A
US2956062A US795598A US79559859A US2956062A US 2956062 A US2956062 A US 2956062A US 795598 A US795598 A US 795598A US 79559859 A US79559859 A US 79559859A US 2956062 A US2956062 A US 2956062A
Authority
US
United States
Prior art keywords
alpha
methyl
pyrrolidyl
grams
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US795598A
Inventor
Carl D Lunsford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AH Robins Co Inc
Original Assignee
AH Robins Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AH Robins Co Inc filed Critical AH Robins Co Inc
Priority to US795598A priority Critical patent/US2956062A/en
Application granted granted Critical
Publication of US2956062A publication Critical patent/US2956062A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Unit S wsPa U ESTERS F AlVIINO ALCOHOLS Carl D. Lnnsford, Richmond, Va., assignor to A. H. Robins Company, Inc., Richmond, Va., a corporation of Virginia No Drawing. Filed Feb. 26, 1959, Ser. No. 795,598
12 Claims. ((31. 260-3263) The present invention relates to esters of amino alcohols, more particularlycertain esters of N.- or l-substituted 3-pyrrolidinols. These novel compounds include the cycloalkyl-aryl-acetates and glycolates of 3-pyrrolidinols. The concept constituting the present invention is illustrated by the following structural formula:
shown above may be readily prepared as illustrated in the examples. below and include salts formed with such' inorganic and organic acids as hydrochloric, hydrobromic, hydriodic, sulfuric, sulfamic, phosphoric, acetic, glycolic, succinic, maleic, malic, citric, tartaric, ascorbic, benzoic,
cinnamic, mandelic, benzilic, diphenylacetic and the like.
Quaternary ammonium salts such as alkyl salts, aralkyl salts, and the like, of the organic. bases illustrated in the general structural formula appearing above may be readily formed by treatment of the organic bases with the ap- 2,956,062 Patented Oct. 11, 1960,
2 acid and separating by fractional crystallization the dandl-forms.,, V
Evaluations of the compounds of the above concept by standard pharmacological tests have indicated the utility thereof as inhibitors of gastrointestinal motility, comparing favorably in potency with 'Methantheline bromide; The compounds are predominantly antagonists ofacetylcholine.
This application isa continuation-in-part of Serial No. 666,250, Lunsford, filed June 17, 1957, entitled Esters of Amino Alcohols, now abandoned.
The present invention is characterized by a particular, esterification of a secondaryalcohol attached directly to a ring carbon in the 3.,position of the pyrrolidine ring fraction. The prior art into which the compounds of the present invention fall can be distinguished. United States Patent 2,655,511, Woodruif, describes N or 1 pyrrolidyl esters where the alkanol group is extra-cyclic to the pyrrolidine ring (where there is a methylene bridge attached to the heterocyclic nitrogen); UnitedjStates Patent 2,695,301, Blicke, teaches benzilates proceeding from the 2 position of the pyrrolidine ring but differs from the present invention in that the alcohol group is primary and extra-cyclic; United States Patent 2,735,847, Blicke, describes diphenyl acetates proceeding from the N or'l position in the pyrrolidine ring and involves extracyclic esterification.
propriate quaternary salt, forming substances, which in- 1 elude, for example, methyl chloride, methyl bromide, methyl iodide, methyl sulfate, methylbenzene-sulfonate, methyl p-toluenesulfonate, ethyl chloride, ethyl bromide, ethyl iodide, n-propyl chloride, n-propyl bromide, n-
propyl iodide, isopropyl bromide, n-butyl chloride, n-butyl bromide, isobutyl bromide, sec.-butyl bromide, n-amyl bromide, n-hexyl chloride, benzyl chloride, benzyl bromide, and ethyl sulfate, yielding respectively the methochloride, methobromide, methiodide, methyl methosulfate, fonate, ethochloride, ethobromide, ethiodide, n-propochloride, n-propobromide, n-propiodide, isopropobromide, n-butochloride, n-butobromide, isobutobromide, sec.-bu tobromide, n-amobromide, n hexochloride, benzochloride, benzobromide, ethosulfate, etc.-
.In the structural formula given above, the asterisks 'serve to point out the asymmetric carbon atoms present in many of the compounds of the present invention. When two asymmetric centers are present, pairs of diastereoisomers are possible. 'with their optically active forms are included within the scope of the present invention.
The twopairs of diastereoisomers are separated and resolution of the diastereoisomers into their optically active forms may be accomplished by combining the methobenzenesulfonate, metho-p-toluenesul- These diastereoisomers, together Therefore, it is an object of this invention to provide novelcycloalkyl-aryl-acetic acid esters of 3-py1'rolidinols. It is a further object of the present invention to provide such esters wherein the alpha carbon of the acetate group may be substituted by an additional radical such as hy-. droxyl and wherein the 3-pyrrolidine portion of the molecule is substituted in the N ortl position; I It is, an additional object of the present invention to provide novel acetylcholine antagonists having satisfactory activity when compared with known compounds currently in use as inhibitors of gastrointestinal motility.
Other objects. of the invention-will become apparent to those skilled in the art to which this invention pertains. Members of the new group of compounds. include the alpha-cycloalkyl-aryl.aceticand glycolicacid esters of 3- pyrrolidinols where the N or 1 position of the pyrrolidine ring substituted by a hydrocarbon radical such as alkyl, cycloalkyl, aralkyl and the like,fpreferably lower alkyl. Referring to'R' in the'above structuralformula, the preferred hydrocarbon radicals are alkyl, especially straight and branched chain lower alkyl radicals, cycloalkyl and aralkyl.
The term lower alkyl is defined toinclude straight and branched chain radicals of 1 -6 carbon atoms inclusive and includes such substituents as methyl, ethyl, isopropyl, tertiary butyl, isoamyl and the like. The term c-ycloalkyLis defined to includepr-irnarily cyclic alkyl radicals contain: ing 5 to 8 carbon atoms inclusive and'encompass'es such substituents as cyclohexyl, cyclopentyl, methyl cyclohexyl, ethyl cyclopentyl, dimethyl-cyclohexyl, and cycloheptyl. Included in the term aralkyl are-such radicals as lower alkyl-substituted mono-carbocyclic aryl compounds such as benzyl, phenethyl, phenpropyl and the like. Preferably, R is a hydrocarbon radical containing less than 8 carbon atoms :and is selected from'the group consisting of lower alkyl,..cycloalkyl and aralkyl. Q
Referringto R in the above structural formula the cycloalkyl hydrocarbon radicals are defined as above; preferably, the cycloalkyl radical contains at least 5 and less than 8 carbon atoms.
.Referring to R in the above structur'alformulaflfin column 1), R" is preferably an hydroxy radical. ,Gener'ally, forreasons of activity the esters in the formof nontoxic, pharmaceutically acceptable acid addition and quaternary ammonium salt compounds; where a 3 in referring to the structural formula in column 1, R is lower alkyl, R is cyclopentyl and R" is hydroxy, are preferred. Among the specifically preferred compounds are: a
1 ethyl 3 pyrrolidyl alpha-cyclopentylpheuylacetate methobrornide.
1 -'methyl 3 pyrrolidyl alpha-cyclopentyl-mandelate hydrochloride 1 methyl 3 pyrrolidyl alpha-cyclopentyl-mandelate methobrornide l-ethyl-S-pyrrolidyl alpha-cyclohexylphenylacetate hydrochloride l-methyl 3 pyrrolidyl alpha-cyclohexylphenylacetate methiodide 1 ethyl 3 -pyrrolidyl alpha-cyclohexylphenylacetate methiodide 1 benzyl 3 pyrrolidyl alpha-cyclohexylphenylacetate methobrornide The alpha carbon of the acetate group preferably is further substituted by a hydroxy radical, i.e., wherein R" is a hydroxy radical. Such compounds may be alternatively viewed as substituted glycolates or mandelates.
A highly preferred compound by reason of activity from these esters having a hydroxy radical on the alpha carbon of the acetate is the 1-rnethyl-3-pyrrolidyl alpha-cyclopentyl-mandelate methobrornide (1-methyl-3-(alpha-cyclopentylphenylhydroxyacetyloxy) pyrrolidine methobromide). This compound was found to be active at a. dilution of about one part in 100,000,000 in counter-acting spasms induced by acetylcholine in isolated intestinal strips. Other preferred compounds include l-methyl-3- pyrrolidyl alpha-cyclopentyl-mandelate hydrochloride and 1-ethyl-3-pyrrolidyl alpha-cyclopentyl-mandelate hydrochloride.
Generally, the N or 1. lower alkyl substituted compounds indicated greater activity and generally the alphacycloalkyl-mandelates were preferred.
The esters of the present invention may be prepared by reaction of a l-hydrocarbon substituted-3-pyrrolidinol of the formulawherein R is as above with an alpha. aryl acetic acid compound of the formula:
wherein R and R are as above and B isv hydroxy, halogen or lower alkoxy.
When B is lower alkoxy, the transesterification reaction is conducted in the presence of a sodium metal catalyst until the theoretical amount of lower alkanol separates. With this exception, the reaction conditions are similar for all variants of starting compounds, i.e., the reactants, used in approximately equimolar amounts, are heated at reflux temperatures for periods of at least about one hour and usually from one to two. hours, preferably using a hydrocarbon solvent as the reaction medium. Theresulting reaction product is extracted with dilute mineral acid,,e.g.
hydrochloric acid, and the resulting extract basified (e.g. with aqueous sodium hydroxide) to yield the free base upon extraction with the appropriate solvent. The acid addition salts and quaternary salts are produced from the base by reaction in solvent of the base and the appropriate acid or quaternizing reagent.
The preparation of the starting N-substituted-3-pyrrolidinols used in the present invention has been previously described in United States Patents 2,830,997 and 2,838,- 521, Lunsford.
The following examples illustrate the preparation of the compounds of the present invention:
All compounds may be prepared by the alternative modifications of the procedure using either the acid or acid chloride, or the lower-alkyl ester of the acid, e.g., the methyl ester.
EXAMPLE l.-1-METHYL-3 -PYRROLIDYL ALPHA- CYCLOHEXYLPHENYLACETATE To a solution of 71 grams (0.3 mole) of alpha-cyclohexylphenylacetyl chloride in toluene were added 35.5 grams (0.35 mole) of l-methyl-3-pyrrolidinol at a dropwise rate with stirring. After complete addition the mixture was refluxed for four hours, cooled and extracted with 3 N hydrochloric acid. The acid extract was basified with aqueous sodium hydroxide and extracted with chloroform. The chloroform layer was washed, dried over sodium sulfate and concentrated. The residue was distilled at reduced pressure. Yield 50 grams (55 percent); boiling point l44-l47 C. at 0.5 mm.
The hydrochloride was precipitated from an ethereal solution of the base with ethereal hydrogen chloride and crystallized from butanone; melting point l53.5154.5 C.
The methiodide quaternary precipitated from an ethereal solution was the base and excess methyl iodide after standing for several hours. It was crystallized from butanone; melting point 169.5-170.5 C.
EXAMPLE 2.--l-n-BUTYL-3-PYRROLIDYL ALPHA- CYCLOPENTYLPHENYLACETATE To a solutionof 89 grams (0.4 mole) of alpha-cyclm pentylphenylacetyl chloride in benzene were added 71.5 grams (0.50 mole) of l-n-butyl-3-pyrrolidinol at a dropwise rate with stirring. After complete addition the mixture was refluxed for two hours, cooled and extracted with 3 N hydrochloric acid. The acid extract was basified with aqueous sodium hydroxide and extracted with ether. The layer was washed, dried over sodium sulfate, and concentrated. The residue was distilled at reduced pressure. Yield grams (67 percent); boiling point -155 C. at 0.1 mm.
The hydrochloride was precipitated from an ethereal solution of the base with ethereal hydrogen chloride and crystallized from butanone; melting point 107.5l09.5 C.
The methobrornide quaternary was precipitated from an ethereal solution of the base and excess methyl bro mide after standing for thirty-six hours. it was crystallized first from an ethyl acetate-ether mixture and then from butanone; melting point 104-106 C.
EXAMPLE 3 .l-BENZYL-3-PYRROLIDYL ALPHA- CYCLOHEXYLPHENYL-ACETATE To a solution of 71 grams (0.3 mole) of alpha-cyclohexylphenylacetyl chloride in toluene were added 62 grams (0.35 mole) of 1-benzyl-3-pyrrolidinol, at a dropwise rate with stirring. After complete addition the mixture was refluxed for four hours, cooled and extracted with 3 N hydrochloric acid. The acid extract was basified with aqueous sodium hydroxide and extracted with chloroform.
70 The chloroform layer was washed, dried over sodium sulfate and concentrated. The residue was distilled at reduced pressure. Yield 45.5 grams (40 percent); boiling point l8718'9 C. at 0.01 mm.
The hydrochloride was precipitated from an ethereal splution of: the base with ethereal hydrogen chloride and crystallized from butanone; melting point 142-143.5 C.
The methyl bromide quaternary precipitated from an ethereal solution of the base and excess methyl bromide, after standing for twenty-four hours, as an oil. This was crystallized from an ethyl acetate-ethermethanol mixture; melting point 183-185 C.
EXAMPLE 4.1-METHYL-3 -PYRROLIDYL ALPHA- CYCLOPENTYLPHENYLACETATE To a solution of 52 grams (0.244 mole) of alpha-cyclopentylphenylacetyl chloride in benzene were added 25 grams (0.248 mole) of 1-methyl-3-pyrrolidinol, at a dropwise rate, with stirring. After complete addition the mixture was refluxed for two hours, cooled and extracted with 3 N hydrochloric acid. The acid extract was basified with aqueous sodium hydroxide and extracted with ether. The ether layer was washed, dried over sodium sulfate, and concentrated. Theresidue was distilled at reduced pressure. Yield 40 grams (63 percent); boiling point 144-147? C. at 0.2 mm. s
The hydrochloride was precipitated as an oil from an ethereal solution of the base with ethereal hydrogen chloride. This was crystallized from a methonol-ethyl acetate mixture and melted at 114-l15 C.
The methyl bromide quaternary was precipitated from an ethereal solution of the base and excess methyl bromide after standing for seventy-two hours. It was purified by recrystallization from butanone and melted at 166.5- 168 C. r
EXAMPLE 5.-1-n-BUTYL-3-PYRROLIDYL ALPHA- CYCLOPENTYLMANDELATE A mixture of 54 grams (0.216 mole) of methyl alphacyclopentylmandelate and 39 grams (0.272 mole) of l-n-butyl-Bpyrrolidinol in 500 ml. of heptane was refiuxed under a Dean and Stark moisture trap, with the addition of four 0.1 gram pieces of sodium at one hour intervals. After five hours refluxing the solution was concentrated at one half volume, diluted with ether and washed with water. The ether layer was dried over sodium sulfate and concentrated. Theresidue was fractionally distilled at reduced pressurel Yield 60 grams (80.5 percent); boiling point 160-165 C. at 0.04 mm.
The hydrochloride was precipitated from an ethereal solution of the base with ethereal hydrogen chloride as an oil. It was crystallized from butanone and melted at 129-130 C.
Analysis.Calcd for C H NO 1-HCl: or, 9.28.
Analysis.Calcd for C H NO -CH Br: Br, 18.15.
Found: Br, 17.98.
A mixture of 42.5 grams (0.17 mole) of methyl alphacyclopentyl mandelate and 18 grams (0.175 mole) of 1-methyl-3-pyrrolidinol in 500 ml. of heptane-was refiuxed under a Dean and Stark moisture trap, with the addition of four 0.1 gram pieces of sodium at one hour intervals. After five hours refluxing the solution was concentrated to one half volume, and extracted with cold 3 N HCl. The acid extract was made alkaline with aqueous sodium hydroxide and extracted with ether which was washed, dried over sodium sulfate, filtered and concentrated. The residue was fractionated at reduced pressure. Yield 33 grams (64%); boiling point 151154 C./0.2 mm. 11 1.5265.
The hydrochloride salt was precipitated as an oil from an ethereal solution of the base with ethereal hydrogen "chloridei It' was crystallized from butanone; melting EXAMPLE 7.--1-ETHYL-3-PYRROLIDYL ALPHA- CYCLOPENTYLMANDELATE HYDROCHLORIDE This compound was prepared according to the method outlined for the methyl derivative above (see Example 6). The base boiled at 162-165 C./0.25 mm. After recrystallization from butanone :the salt melted 160- 161.5 C.
Analysis.--Calcd for C H NO Cl, 10.02. Found: Cl-, 9.82.
EXAMPLE 8.1 CYCLOHEXYL-3-PYRROLIDYL ALPHA CYCLOPENTYLMANDELATE HYDRO- CHLORIDE.
This compound was prepared according to the method outlined for the methyl derivative above as in Example 6. The base boiled at 193-195 C./0.038 mm. After recrystallization from butanone and absolute ethanol the salt melted 2l2213.5 C.
Analysis.Calcd for C H NO -HC1: Cl", 8.69. Found: Cl, 8.81.
EXAMPLE 9.lMETHYL-3-PYRROLIDYL ALPHA- CYCLOHEXYLMANDELATE A mixture of 10 grams (0.0403 mole) of methyl alphacyclohexylmandelate and 5 grams (0.0493 mole) of N- rnethyl-3-pyrrolidin0l' in ml. of n-heptane was refluxed for five hours under a Dean and Stark moisture trap. At approximately equal intervals starting at zero time three approximately 0.1 gram pieces of sodium metal were added to the reaction. At completion of the reflux time the heptane solution was extracted wtih icecold 3 N hydrochloric acid. The acid extract was basi-. fied with saturated aqueous potassium carbonate and extracted with ether. The ether extract was washed, dried over magnesium sulfate and concentrated. The residual oil was distilled at -163 C./ 0.3 mm. giving an amber oil product. Yield 8.7 grams (68%).
The hydrochloride salt was precipitated as a crystalline solid from an ethereal solution of the base with ethereal hydrogen chloride. It was crystallized from a butane methanol mixture; M.'P. 206-207 C. a I
Analysis.-Calcd for C H NO -HCl: C-l"',- 10.02. Found: c1,10.00. I I
The methyl bromide quaternary was prepared-by saturating a solution of the free base in dry'- ethyl etherfwith methyl bromide and allowing the solution to stand 15 The product precipitated as white crystals' 'and hours. was recrystallized from butanone; M.P. 253-255 C (d).
This decomposition range varies with the rate at which the sample is heated.
Analysis.Calcd for C H NO -Br: Br 19.38. Found: Br", 19.27. i a As pointed out in column 1, those compounds which have two asymmetric centers are capable of existing in two diastereoisomeric forms. These two-forms can be separated by fractional crystallization as shown in the following exam l ture trap. At approximately equal intervals, starting at zero time, three approximately 0.1 gram pieces of sodium metal were added to the reaction. At completion of the reflux time the heptane solution was extracted with ice cold 3 N hydrochloric acid. The acid extract was basified with aqueous sodium carbonate and extracted with ether. The ether extract was washed, dried over sodium sulfate and concentrated. The residual oil was distilled at 1571-60 C./0.05- mm., giving an amber oil product. Yield 31.7 grams (56%). V
This material was converted to the hydrochloride salt by precipitation as a crystalline solid from an ethereal solution of the base with ethereal hydrogen chloride. This material was fractionally crystallized from methyl ethyl ketone and from an ethyl acetate methanol mixture. High and low melting isomers were obtained:
Other compounds within the scope of the invention are shown in Table I. In each instance the free base as well as the indicated acid addition or quaternary salt was prepared.
Table I R C Hz-N-R C-C O O CH I A CH2CH7 R R A Salt Calculated f01'- Pegcient Found M.W M.P., C
CH3 Cy-CsHu H HCI CwHwNOrHCl 16. 49 10. 46 337. 88 153. 5-154. 5 C 115 cy-CsHu H 1101 CzoHzoN'Oz-HCl 10. 01 10. 14 351. 91 125 -127. 5 i-CsH'; CY-CaHn H HCI CzrHmNOz-HCI 9. 69 9. 67 365. 9.1 164 -167 D-C4Ha Cy-CaHu H H01 CwzHmNOz H01 9: 34 9. 28 379. 96 100 -151 i-C4Ho Cy-CsHn H H01 CHHKJNO: H01 9. 34 9. 27 379. 96 139. 5-1415 t-C4H9 (Dy-C 11 H I'ICI CzzHzgNOz H01 9. 34 9. 43 379. 96 141 -142 (By-0 11 1 cy-OuH H HCl C24H3 NO2 HCl 8. 73 8. 62 405. 98 226 -227. 5 CaHsCHz Cy-CeHrr H V HCl C25H31NO HC1 8. 57 8. 69 413. 93 142 -143. 5 CH3 CY-CgHq H H01 C15H25NO2 HCl 10. 95 10. 93 323. 85 114 -115. 5 C2115 CY-C5H9 H 1101 OmHzrNOz-HCI 10. 49 10. 31 337. 88 113 --114 11-C4H9 Cy-CsHa H H01 C2iH31NO2-HC1 9. 69 9. 67 365. 93 107. 5-109. 5 CY-CsHn (.y-C5Hq H H01 Cz3H33NOz-HC1 9. Q5 8. 90 391. 97 191 192. 5 C5H CH2 Cy-C5H9 H H01 CttHtONOz-HCl 8. 86 8. 70 399. 94 138 -139 CH3 Cy-CuHu H. CH3]: CZOHKUNO'g-I 28. 62 28. 67 443. 37 169. 5-176 5 CH3 cy-O5H H CHsBI' C aHaoNOa-Bl 26. 16 20. 2S 2116. 36 177. 5-179 C2115 Cy-CgH H CH3]: CmHazNOrI 27. 74 27. 70 457. 40 130 133 1-C4H9 Cy-CaHn H CHaBI CnHaeNOrBl 18. 23 17. 93 4'33. 168. 5-170 t-CtHe Cy-CuHn H CH3B1 CggHaaNOg- B1 18. 23 18. 12 438. 45 177 -178 CoH5CHz Cy-CaHn H CHaB! CznHuNOz-BI 16. 92 16. 62 472. 46 183 -185 H3 cy-O H H CHzBI CmHzgNOz-Br 20. 96 21. 13 382. 34 166. 5-163 CgH5 try-C514 H CHsBI CZUHanNOzBl 26. 16 26. 14 396. 37 152. 5-154 n-C Hq Cy-C H9 H CHaBI' CMHIHNOziBI 18. 83 18. 72 424. 42 167. 5-108. 5 cy-CgHn 0y-C5H9 H CHaBI HHMNOL'BT 17. 74 18. O1 448. 45 191. 5-193 CeH5CHz cy-C H H CHaBr Cz5H32NO2-Br 17. 51 17. 67 407. 43 175. 5-176. 5 H3 (By-C5119 OH H01 CrgH aNOa-HCI 10. 43 10. 30 509. 85 170 -171. 5 C2115 (fly-C 119 OH HCl CmHzlNOs-HCJ 16. 62 9. 82 .553. 88 160 -161. 5 H'CJHQ (By-C5119 OH 1101 CmHgzNOg-HCI 9. 2S 9. 17 381. 93 129 -13[) (fly-05H ey-C H OH H01 CuHsaNOrHCl 8. 69 8. 81. 467. 97 212 -213. 5 CH3 (III-C 11 OH CHzBI CnHrsNOa-BI 26. 66 19. 78 398. 3-1 193 494. 5 D'C-IHG (y-C5110 OH CHaBI' CzgHzqNOa-BI 18. 15 17. 98 140. 42 176 -177. 5 CBH5CH2 Cy-C H9 OH CHaBr C251'I32NO3BI' 16. 84 16. S3 474. 43 173 -175 cy-CuHn CY-C H9 OH CHaBr C24H35NO3'B1' 17. 13 16. 93 466. 4.5 193 196 CH3 C"-C6Hr1 OH HC1 CIQHQ'INOZ'HCl 10. 02 10. O0 353. S6 206 -2U7 CH3 (By-09H OH CHgBl CzuHeuNOz-Br 19. 38 19.27 412. 36 253 255 0211561401111) cyIhI-In OH H01 C1aH2gNO3-C1 9. 64 9. 68 367. 91 184 185 CgHaQi-fOlfll) (Dy-C51 1 OH IIC-l CzoHzqNOs- C1 9. 64 9. 65 367. 91 219 -220. 5 021-15 cy-C H OH CHaBl' CzrHtzNOyBt 18. 74 18. 59 426. 39 181 -182. 5
2.5 grams of material, M.P. 184185, and 13.8 grams of material melting 219-2205". A mixture of these two isomers melted at 178182 C.
Analysis of high melting is0mer.Calcd for C H NO -HCl: C, 65.29; H, 8.22. Found C, 65.55; H, 8.33.
Analysis of low melting is0mer.Calcd for c, H,,N0 -Hc1; C, 65.29; H, 8.22. Found: C, 65.45; H, 8.39.
The low melting isomer is designated the alpha (0:) form and the high melting isomer is referred to as the beta (13) form in Table I.
In the same manner as given in the preceding examples, by reacting the appropriate l-hydrocarbon substituted-3- pyrrolidinol with the appropriate esterifying agent, additional compounds within the scope of the general structural formula are prepared.
Representative products prepared from the chosen starting materials are as follows:
alpha-cyclopentylphenylacetate In evaluating the compounds of the present invention pharmacologically the following experimental testing procedure was utilized.
ISQLATED GUINEA PIG ILEUM STUDIES Guinea pigs were killed by a blow on the head. The ileum was removed and terminal segments were suspended in a ml. smooth muscle bath containing Tyrodes solution which was maintained at 37 C. The bath was aerated by bubling a continuous stream of oxygen through it. Intestinal activity was recorded by a balanced ink-writing lever yielding five-fold magnification on a Gorrell and Gorrell kymograph operated at speed P.
Aqueous solutions of all materials were employed in these studies. Essentially, the method consisted of initially standardizing submaximal contractions of the isolated ileum to acetylchlorine chloride, histamine phosphate, serotonin creatinine sulfate and barium chloride. The test material was then introduced into the bath and two minutes later the ileum was again challenged with the various spasmogens. Tests were made at various concentrations of the compounds in the bath until it was possible to differentiate their relative activity as antagonists of the spasmogens.
The results of the pharmacological testing indicate that the compounds are predominantly acetylcholine antagonists and are eflective in inhibiting gastrointestinal motility in vivo and in vitro. In general, the compounds compared favorably in potency with Methantheline bromide under the conditions of these tests.
Various modifications may be made in the compounds of the present invention without departing from the spirit and scope thereof, and it is to be understood that the invention is limited only by the scope of the appended claims.
I claim:
1. A compound selected from the group consisting of esters of B-pyrrolidinols having the structural formula wherein R is a hydrocarbon radical selected from the group consisting of lower alkyl, phenylalkyl containing up to nine carbon atoms inclusive, and cycloalkyl containing five to eight carbon atoms inclusive and having five to seven carbon atoms inclusive in the ring.
R is a cycloalkyl hydrocarbon radical containing five to eight carbon atoms inclusive and having five to seven carbon atoms inclusive in the ring, and
R" is a radical selected from the group consisting of hydrogen and hydroxyl; and nontoxic acid addition and lower-alkyl and benzyl quaternary ammonium salts thereof.
2. l-methyl- 3 -pyrrolidyl alpha-cyclopentylmandelate methobromide.
3. 1-methyl-3 -pyrrolidyl alpha-cyclopentylmandelate hydrochloride.
4. 1-ethyl-3-pyrrolidyl alpha-cyclopentylphenylacetate methobromide.
5. l-methyl 3 pyn'olidyl alpha cyclohexylphenylacetate methiodide.
6. l-methyl 3 pyrrolidyl alpha cyclohexylphenylacetate hydrochloride.
7. l-ethyl 3 py-rrolidyl alpha cyclohexylphenylacetate methiodide.
8. l-benzyl-3-pyrrolidyl alpha-cyclohexylphenylacetate methobromide.
9. 1-lower-alkyl-3 pyrrolidyl cycloalkylmandelate having the structural formula:
cycloalkyl lLwer-alkyl wherein the cycloalkyl radical contains five to eight carbon atoms, inclusive, and has five to seven carbon atoms, inclusive, in the ring.
10. Non-toxic acid addition salt of a compound of claim 9.
11. Non-toxic lower-alkyl quaternary ammonium salt of a compound of claim 9.
12. l-methyl 3-pyrrolidyl alpha-cyclopentylmandelate.
References Cited in the file of this patent Richters Organic Chemistry, vol. 3, pp. 3 to 4 (1923).

Claims (1)

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF ESTERS OF 3-PYRROLIDINOLS HAVING THE STRUCTURAL FORMULA
US795598A 1959-02-26 1959-02-26 Esters of amino alcohols Expired - Lifetime US2956062A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US795598A US2956062A (en) 1959-02-26 1959-02-26 Esters of amino alcohols

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US795598A US2956062A (en) 1959-02-26 1959-02-26 Esters of amino alcohols

Publications (1)

Publication Number Publication Date
US2956062A true US2956062A (en) 1960-10-11

Family

ID=25165953

Family Applications (1)

Application Number Title Priority Date Filing Date
US795598A Expired - Lifetime US2956062A (en) 1959-02-26 1959-02-26 Esters of amino alcohols

Country Status (1)

Country Link
US (1) US2956062A (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) * 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
US3138614A (en) * 1961-12-18 1964-06-23 Lilly Co Eli Salts of 1, 1-dimethyl-3-pyrrolidyl phenyl-2-thienylglycolate
US3211747A (en) * 1961-10-10 1965-10-12 Union Carbide Corp N-carbamylmethyl-maleimides
US4990683A (en) * 1986-10-27 1991-02-05 A. H. Robins Company, Incorporated Process for preparing 3-pyrrolidinols
WO1998021183A1 (en) * 1996-11-11 1998-05-22 Noe Christian R Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
US6395757B1 (en) 1998-08-31 2002-05-28 Arthur M. Bobrove Method for treating hot flashes in humans
US6420392B1 (en) 1994-01-06 2002-07-16 Millennium Pharmaceuticals, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
WO2003087094A2 (en) * 2002-04-16 2003-10-23 Almirall Prodesfarma Ag Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
US20030220400A1 (en) * 1996-11-11 2003-11-27 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
WO2004056767A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
WO2006092617A1 (en) * 2005-03-03 2006-09-08 Sosei R & D Ltd. Crystallisation and purification of glycopyrronium bromide
WO2008000482A1 (en) 2006-06-30 2008-01-03 Novartis Ag Compositions of glycopyrronium salt for inhalation
US20080063719A1 (en) * 2004-04-30 2008-03-13 Vectura Limited Pharmaceutical Compositions
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20080267886A1 (en) * 2004-05-18 2008-10-30 Stephen Paul Collingwood Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
US20090005577A1 (en) * 2007-06-29 2009-01-01 Nikolai Kraiouchkine Method of producing 1-substituted 3-pyrrolates
US20090227590A1 (en) * 2004-12-24 2009-09-10 Neil John Press Quaternary ammonium salts as m3 antagonists
EP2112137A1 (en) 2008-04-25 2009-10-28 Saltigo GmbH Method for producing quarternary salts from mandelic acid piperidyl esters
WO2010115937A1 (en) 2009-04-09 2010-10-14 Novartis Ag Process for preparing pyrrolidinium salts
WO2010138868A2 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
WO2011076843A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011157536A1 (en) 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Process for the preparation of glycopyrronium chloride
WO2011157387A1 (en) 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Crystal form of glycopyrronium chloride
WO2012106575A1 (en) 2011-02-04 2012-08-09 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN103012231A (en) * 2012-12-14 2013-04-03 沈阳药科大学 Preparation method and application of glycopyrronium bromide chiral antipode
CN103159659A (en) * 2011-12-19 2013-06-19 沈阳药科大学 Preparation method of muscarinic receptor antagonist glycopyrronium bromide
EP2607351A1 (en) 2011-12-22 2013-06-26 Cerbios-Pharma S.A. Continuous process for the alkylation of cyclic tertiary amines
EP2682103A2 (en) 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol
EP2682129A2 (en) 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
EP2682100A2 (en) 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Inhalation Compositions Comprising Muscarinic Receptor Antagonist
WO2014062143A2 (en) 2012-10-19 2014-04-24 Mahmut Bilgic Anticholinergic agent combinations
WO2014077787A1 (en) 2012-11-16 2014-05-22 Mahmut Bilgic Combinations including abeta2 agonist and glycopyrrolate
WO2014141135A1 (en) 2013-03-14 2014-09-18 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
WO2014147541A3 (en) * 2013-03-19 2015-02-19 Mahesh Kandula Compounds and compositions for the treatment of peptic ulcers and gastrointestinal diseases
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US9006461B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2015101576A1 (en) 2013-12-30 2015-07-09 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US20160052879A1 (en) * 2014-08-20 2016-02-25 Dermira, Inc. Process for production of glycopyrronium tosylate
WO2016102174A1 (en) * 2014-12-24 2016-06-30 Laboratorios Lesvi, S.L. Process for preparing (3rs)-3-[(2sr)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide
US9610278B2 (en) 2013-02-28 2017-04-04 Dermira, Inc. Glycopyrrolate salts
WO2018019803A1 (en) 2016-07-29 2018-02-01 Laboratorios Lesvi, S.L. Particle size stabilization process
WO2018026869A1 (en) 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds
WO2018033598A1 (en) 2016-08-17 2018-02-22 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2018154597A1 (en) * 2017-02-22 2018-08-30 Gbr Laboratories Pvt. Ltd. Process for synthesis of glycopyrronium bromide
EP3415127A1 (en) 2007-10-18 2018-12-19 Rose U, LLC Topical glycopyrrolate formulations and a wipe containing thereof
US10695321B2 (en) 2011-03-04 2020-06-30 Heptares Therapeutics Limited Use of glycopyrrolate for treating tachycardia
EP3689332A1 (en) 2014-09-09 2020-08-05 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
WO2022111500A1 (en) * 2020-11-26 2022-06-02 Rezubio Pharmaceuticals Co., Ltd Anticholinergic agents
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2023283438A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB483258A (en) * 1936-06-08 1938-04-14 Arthur George Bloxam Manufacture of basic esters of polyarylacetic acids
GB532943A (en) * 1938-08-05 1941-02-04 Chem Ind Basel Manufacture of alkamine esters and quaternary salts thereof
US2317804A (en) * 1938-12-31 1943-04-27 Reppe Walter N-vinyl lactams
US2792399A (en) * 1954-05-29 1957-05-14 Bofors Ab Anilides of heterocyclic compounds
US2799679A (en) * 1955-04-28 1957-07-16 Bofors Ab Process of preparing amides of heterocyclic carboxylic acids
US2816895A (en) * 1954-11-30 1957-12-17 Hoechst Ag Basic benzilic esters and a process of preparing them
GB788126A (en) * 1955-09-29 1957-12-23 Schering Corp Quaternary salts of piperidyl esters
BE555178A (en) * 1956-02-22 1960-02-12 Parke Soc NEW CHEMICAL COMPOUNDS HAVING USEFUL THERAPEUTIC PROPERTIES AND METHODS FOR PREPARING THEM.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB483258A (en) * 1936-06-08 1938-04-14 Arthur George Bloxam Manufacture of basic esters of polyarylacetic acids
GB532943A (en) * 1938-08-05 1941-02-04 Chem Ind Basel Manufacture of alkamine esters and quaternary salts thereof
US2317804A (en) * 1938-12-31 1943-04-27 Reppe Walter N-vinyl lactams
US2792399A (en) * 1954-05-29 1957-05-14 Bofors Ab Anilides of heterocyclic compounds
US2816895A (en) * 1954-11-30 1957-12-17 Hoechst Ag Basic benzilic esters and a process of preparing them
US2799679A (en) * 1955-04-28 1957-07-16 Bofors Ab Process of preparing amides of heterocyclic carboxylic acids
GB788126A (en) * 1955-09-29 1957-12-23 Schering Corp Quaternary salts of piperidyl esters
BE555178A (en) * 1956-02-22 1960-02-12 Parke Soc NEW CHEMICAL COMPOUNDS HAVING USEFUL THERAPEUTIC PROPERTIES AND METHODS FOR PREPARING THEM.

Cited By (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) * 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
US3211747A (en) * 1961-10-10 1965-10-12 Union Carbide Corp N-carbamylmethyl-maleimides
US3138614A (en) * 1961-12-18 1964-06-23 Lilly Co Eli Salts of 1, 1-dimethyl-3-pyrrolidyl phenyl-2-thienylglycolate
US4990683A (en) * 1986-10-27 1991-02-05 A. H. Robins Company, Incorporated Process for preparing 3-pyrrolidinols
US6420392B1 (en) 1994-01-06 2002-07-16 Millennium Pharmaceuticals, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6307060B1 (en) * 1996-11-11 2001-10-23 Christian Noe Enantiomerically pure basic N-heterocyclic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US7253182B2 (en) * 1996-11-11 2007-08-07 Sofotec Gmbh & Co. Kg Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US20030220400A1 (en) * 1996-11-11 2003-11-27 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
CN100391942C (en) * 1996-11-11 2008-06-04 索佛特克两合公司 Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing same and their use in medicaments
WO1998021183A1 (en) * 1996-11-11 1998-05-22 Noe Christian R Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
US6395757B1 (en) 1998-08-31 2002-05-28 Arthur M. Bobrove Method for treating hot flashes in humans
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
WO2003087094A3 (en) * 2002-04-16 2004-03-18 Almirall Prodesfarma Sa Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
AU2003233967B2 (en) * 2002-04-16 2009-08-06 Laboratorios Almirall, S.A. Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors
US20070129420A1 (en) * 2002-04-16 2007-06-07 Almirall Prodesfarma Sa New pyrrolidinium derivatives
US20050282875A1 (en) * 2002-04-16 2005-12-22 Maria Prat Quinones Pyrrolidinium derivatives
US7192978B2 (en) 2002-04-16 2007-03-20 Almirall Prodesfarma Ag Pyrrolidinium derivatives
WO2003087094A2 (en) * 2002-04-16 2003-10-23 Almirall Prodesfarma Ag Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
WO2004056767A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US20060194862A1 (en) * 2002-12-23 2006-08-31 Anita Mehta 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US20080063719A1 (en) * 2004-04-30 2008-03-13 Vectura Limited Pharmaceutical Compositions
EP3603634A1 (en) 2004-05-18 2020-02-05 Novartis AG Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
US20080267886A1 (en) * 2004-05-18 2008-10-30 Stephen Paul Collingwood Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
US20090227590A1 (en) * 2004-12-24 2009-09-10 Neil John Press Quaternary ammonium salts as m3 antagonists
US8153669B2 (en) * 2004-12-24 2012-04-10 Novartis Ag Quaternary ammonium salts as M3 antagonists
JP2008531674A (en) * 2005-03-03 2008-08-14 ソーセイ アールアンドディ リミテッド Crystallization and purification of glycopyrronium bromide
CN101133021B (en) * 2005-03-03 2011-01-19 索塞R&D有限公司 Crystallisation and purification of glycopyrronium bromide
US20080227988A1 (en) * 2005-03-03 2008-09-18 Andrew Douglas Baxter Crystallisation and Purification of Glycopyrronium Bromide
WO2006092617A1 (en) * 2005-03-03 2006-09-08 Sosei R & D Ltd. Crystallisation and purification of glycopyrronium bromide
US8846954B2 (en) 2005-03-03 2014-09-30 Sosei R&D Ltd. Crystallisation and purification of glycopyrronium bromide
NO340220B1 (en) * 2005-03-03 2017-03-20 Sosei R&D Ltd Crystalline glycopyrronium bromide
WO2008000482A1 (en) 2006-06-30 2008-01-03 Novartis Ag Compositions of glycopyrronium salt for inhalation
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20090005577A1 (en) * 2007-06-29 2009-01-01 Nikolai Kraiouchkine Method of producing 1-substituted 3-pyrrolates
EP3415127A1 (en) 2007-10-18 2018-12-19 Rose U, LLC Topical glycopyrrolate formulations and a wipe containing thereof
DE102008020746A1 (en) 2008-04-25 2009-10-29 Saltigo Gmbh Process for the preparation of quaternary salts of piperidyl esters of mandelic acid
US20090270629A1 (en) * 2008-04-25 2009-10-29 Saltigo Gmbh Process for preparing quaternary salts of piperidyl esters of mandelic acid
EP2112137A1 (en) 2008-04-25 2009-10-28 Saltigo GmbH Method for producing quarternary salts from mandelic acid piperidyl esters
US8309732B2 (en) 2008-04-25 2012-11-13 Saltigo Gmbh Process for preparing quaternary salts of piperidyl esters of mandelic acid
RU2554878C2 (en) * 2009-04-09 2015-06-27 Новартис Аг Method of producing pyrrolidinium salts
EP2417106B1 (en) 2009-04-09 2016-11-30 Novartis AG Process for preparing pyrrolidinium salts
JP2015007081A (en) * 2009-04-09 2015-01-15 ノバルティス アーゲー Process for preparing pyrrolidinium salt
WO2010115937A1 (en) 2009-04-09 2010-10-14 Novartis Ag Process for preparing pyrrolidinium salts
US20120022127A1 (en) * 2009-04-09 2012-01-26 Thomas Allmendinger Process for preparing pyrrolidinium salts
US20110023876A1 (en) * 2009-05-29 2011-02-03 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110132356A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting b2 adrenergic receptor agonists and associated methods and systems
US8324266B2 (en) 2009-05-29 2012-12-04 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110135737A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US20110132357A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
EP3111927A1 (en) 2009-05-29 2017-01-04 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
WO2010138868A2 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
EP3106149A1 (en) 2009-05-29 2016-12-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
EP3111926A1 (en) 2009-05-29 2017-01-04 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
US8703806B2 (en) 2009-05-29 2014-04-22 Pearl Therapeutics, Inc. Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
WO2011076843A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
WO2011157536A1 (en) 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Process for the preparation of glycopyrronium chloride
WO2011157387A1 (en) 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Crystal form of glycopyrronium chloride
WO2012106575A1 (en) 2011-02-04 2012-08-09 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
US10695321B2 (en) 2011-03-04 2020-06-30 Heptares Therapeutics Limited Use of glycopyrrolate for treating tachycardia
CN103159659A (en) * 2011-12-19 2013-06-19 沈阳药科大学 Preparation method of muscarinic receptor antagonist glycopyrronium bromide
JP2013133335A (en) * 2011-12-22 2013-07-08 Cerbios - Pharma Sa Continuous process for alkylation of cyclic tertiary amine
EP2607351A1 (en) 2011-12-22 2013-06-26 Cerbios-Pharma S.A. Continuous process for the alkylation of cyclic tertiary amines
EP2682103A2 (en) 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007769A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and glucose anhydrous
EP2682100A2 (en) 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Inhalation Compositions Comprising Muscarinic Receptor Antagonist
EP2682129A2 (en) 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
WO2014062143A2 (en) 2012-10-19 2014-04-24 Mahmut Bilgic Anticholinergic agent combinations
WO2014077787A1 (en) 2012-11-16 2014-05-22 Mahmut Bilgic Combinations including abeta2 agonist and glycopyrrolate
CN103012231B (en) * 2012-12-14 2015-08-05 沈阳药科大学 The preparation method and application of Glycopyrronium Bromide chiral enantiomer
CN103012231A (en) * 2012-12-14 2013-04-03 沈阳药科大学 Preparation method and application of glycopyrronium bromide chiral antipode
US11291651B2 (en) 2013-02-28 2022-04-05 Journey Medical Corporation Glycopyrrolate salts
US10548875B2 (en) 2013-02-28 2020-02-04 Dermira, Inc. Glycopyrrolate salts
US10543192B2 (en) 2013-02-28 2020-01-28 Dermira, Inc. Glycopyrrolate salts
US9259414B2 (en) 2013-02-28 2016-02-16 Dermira, Inc. Glycopyrrolate salts
US10004717B2 (en) 2013-02-28 2018-06-26 Dermira, Inc. Glycopyrrolate salts
US9006461B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US9610278B2 (en) 2013-02-28 2017-04-04 Dermira, Inc. Glycopyrrolate salts
US11291652B2 (en) 2013-02-28 2022-04-05 Journey Medical Corporation Glycopyrrolate salts
WO2014141135A1 (en) 2013-03-14 2014-09-18 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US9744178B2 (en) 2013-03-14 2017-08-29 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2014147541A3 (en) * 2013-03-19 2015-02-19 Mahesh Kandula Compounds and compositions for the treatment of peptic ulcers and gastrointestinal diseases
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
WO2015101576A1 (en) 2013-12-30 2015-07-09 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3384898A1 (en) 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3566694A1 (en) 2013-12-30 2019-11-13 Chiesi Farmaceutici S.p.a. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10294201B2 (en) 2014-08-20 2019-05-21 Dermira, Inc. Process for production of glycopyrronium tosylate
US9926270B2 (en) * 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
US11542232B2 (en) 2014-08-20 2023-01-03 Journey Medical Corporation Process for production of glycopyrronium tosylate
US20160052879A1 (en) * 2014-08-20 2016-02-25 Dermira, Inc. Process for production of glycopyrronium tosylate
EP3689332A1 (en) 2014-09-09 2020-08-05 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
US10131630B2 (en) 2014-12-24 2018-11-20 Laboratorios Lesvi, S.L. Process for preparing (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide
WO2016102174A1 (en) * 2014-12-24 2016-06-30 Laboratorios Lesvi, S.L. Process for preparing (3rs)-3-[(2sr)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide
WO2018019803A1 (en) 2016-07-29 2018-02-01 Laboratorios Lesvi, S.L. Particle size stabilization process
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process
WO2018026869A1 (en) 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds
WO2018033598A1 (en) 2016-08-17 2018-02-22 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2018154597A1 (en) * 2017-02-22 2018-08-30 Gbr Laboratories Pvt. Ltd. Process for synthesis of glycopyrronium bromide
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
WO2022111500A1 (en) * 2020-11-26 2022-06-02 Rezubio Pharmaceuticals Co., Ltd Anticholinergic agents
CN116669721A (en) * 2020-11-26 2023-08-29 宁康瑞珠生物制药(珠海)有限公司 Anticholinergic agent
WO2023283438A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023283439A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023283441A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
EP4197528A1 (en) 2021-07-09 2023-06-21 AstraZeneca Pharmaceuticals LP Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Similar Documents

Publication Publication Date Title
US2956062A (en) Esters of amino alcohols
US5030649A (en) 2-aminoethylamine derivatives, compositions of the same and use of said compounds in medicine
US5001133A (en) Benzoic acid derivatives
EP0505868B1 (en) N-Acyl-alpha-aminoacids derivatives
US4826819A (en) Piperidine analgesics
US4879300A (en) Novel piperidine derivatives
US4188485A (en) 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds
US4801585A (en) Cyclic carboxamide derivatives and their use as analgesics
PT94121A (en) PROCESS FOR THE PREPARATION OF PHENOL DERIVATIVES TO PROMOTE THE HUMAN NERVE GROWTH FACTOR
EP0330360B1 (en) 1,2,3,4-Tetrahydroisoquinolines, processes for their preparation, and their use as kappa-receptor agonists
FI68229B (en) ANALOGIFICANT FARING FRAMSTAELLNING AV NYA THERAPEUTIC EQUIPMENT DERIVATIVES AV PERHYDRO-AZA-HETEROCYKLER
Atkinson et al. Parasympatholytic (anticholinergic) esters of the isomeric 2-tropanols. 1. Glycolates
US5254564A (en) Substituted isoquinoline compounds, pharmaceutical composition and method of use in treating pain in mammals
EP0361791A2 (en) Azacyclic derivatives useful as medicaments
CA1055037A (en) Pyrrolidine derivatives
US4937260A (en) Benzamido-derivatives
US5025021A (en) 1,2-dideoxy-2-fluoronojirimycin as glycosidase inhibitors
US3557127A (en) Substituted cyclohexenes,derivatives thereof and processes for obtaining same
NO129929B (en)
US3301869A (en) Methobromide and hydrochloride of 1-ethyl-3-pyrrolidyl benzilate
Green et al. Synthesis and pharmacological properties of a series of 2-substituted aminomethyl-1, 4-benzodioxanes
WO1990007502A1 (en) Decahydroisoquinoline compounds
US2903460A (en) Pyrazolone derivatives
CA2065086A1 (en) Cycloalkylurea compounds
US3591602A (en) Pyrrolidine compounds